{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/prescribing-information/dipyridamole/","result":{"pageContext":{"chapter":{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole","depth":2,"htmlHeader":"<!-- begin field 9afa8db4-868d-4461-be65-a781008e7efc --><h2>Dipyridamole</h2><!-- end field 9afa8db4-868d-4461-be65-a781008e7efc -->","summary":"","htmlStringContent":"<!-- begin item 1796e01d-ee9a-4ff4-91b9-a781008e7e2e --><!-- end item 1796e01d-ee9a-4ff4-91b9-a781008e7e2e -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"85828cd6-6943-58a7-9657-71760be76497","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"dbe2603d-c11c-5a12-a64e-8d380441536e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9a1c4c15-9060-4152-8831-a781008ffe14 --><h3>Contraindications and cautions</h3><!-- end field 9a1c4c15-9060-4152-8831-a781008ffe14 -->","summary":"","htmlStringContent":"<!-- begin item 730b8756-9718-417a-b160-a781008ffcee --><!-- begin field 148105e5-ed28-41ba-81a0-a781008ffe14 --><ul><li><strong>Do not prescribe dipyridamole to people with:</strong><ul><li>Cardiac conduction difficulties or dysrhythmias.</li></ul></li><li><strong>Prescribe dipyridamole with caution to people with:</strong><ul><li>Aortic stenosis.</li><li>Coagulation disorders.</li><li>Heart failure.</li><li>Hypertension.</li><li>Left ventricular outflow obstruction.</li><li>Migraine.</li><li>Myasthenia gravis.</li><li>Unstable angina, or a recent myocardial infarction.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>] </p><!-- end field 148105e5-ed28-41ba-81a0-a781008ffe14 --><!-- end item 730b8756-9718-417a-b160-a781008ffcee -->","subChapters":[]},{"id":"4b4c4263-75d3-5e36-abd9-03530a5a4329","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3e48a997-7f43-4e3f-ab66-a78100902b7b --><h3>Adverse effects </h3><!-- end field 3e48a997-7f43-4e3f-ab66-a78100902b7b -->","summary":"","htmlStringContent":"<!-- begin item 62ec4176-4df5-4f06-a764-a78100902aae --><!-- begin field 17fb9824-2825-45a8-99ab-a78100902b7b --><ul><li><strong>Cardiac </strong>— angina pectoris (common); tachycardia (frequency unknown).</li><li><strong>Gastrointestinal </strong>— diarrhoea, nausea (very common); vomiting (common).</li><li><strong>Nervous system</strong> — headache, dizziness (very common).</li><li><strong>Other adverse effects include:</strong><ul><li>Bronchospasm.</li><li>Hypersensitivity, angioedema.</li><li>Hypotension, hot flush.</li><li>Myalgia.</li><li>Post-procedural/operative haemorrhage.</li><li>Rash, urticaria.</li><li>Thrombocytopenia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 17fb9824-2825-45a8-99ab-a78100902b7b --><!-- end item 62ec4176-4df5-4f06-a764-a78100902aae -->","subChapters":[]},{"id":"76391ed9-969a-504f-a327-959dcc08103d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6d9a5825-cb27-4090-81e7-a78100904e68 --><h3>Drug interactions </h3><!-- end field 6d9a5825-cb27-4090-81e7-a78100904e68 -->","summary":"","htmlStringContent":"<!-- begin item 9fbb05f3-e1ab-40ff-9c4c-a78100904d64 --><!-- begin field b53c9df2-9002-45dc-989c-a78100904e68 --><ul><li><strong>Cholinesterase inhibitors</strong> (neostigmine, pyridostigmine) — concurrent use with dipyridamole may antagonise these drugs. Dipyridamole should be used with caution in people with myasthenia gravis.</li><li><strong>Dobutamine </strong>— potentially hazardous hypotension if taken with dipyridamole. Avoid concurrent use.</li><li><strong>Drugs which raise the gastric pH </strong>(antacids, cimetidine, omeprazole) — bioavailability of immediate release dipyridamole may be reduced. Modified release preparations of dipyridamole are not affected.</li><li>Increased risk of bleeding if clopidogrel is combined with other drugs that also increase the risk of bleeding. Examples include: <ul><li>Antiplatelets — prasugrel, ticagrelor.</li><li>Oral and parenteral anticoagulants — warfarin, dabigatran, heparin.</li><li>Selective serotonin reuptake inhibitors (SSRIs) — citalopram, sertraline.</li><li>Serotonin and noradrenaline reuptake inhibitors (SNRIs) — venlafaxine, duloxetine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field b53c9df2-9002-45dc-989c-a78100904e68 --><!-- end item 9fbb05f3-e1ab-40ff-9c4c-a78100904d64 -->","subChapters":[]},{"id":"9a9e51d5-b9df-5341-bfa2-139981de1eb5","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field f2c5b748-7f8d-45a0-a864-a8e801081132 --><h3>Pregnancy and breastfeeding</h3><!-- end field f2c5b748-7f8d-45a0-a864-a8e801081132 -->","summary":"","htmlStringContent":"<!-- begin item a6c25675-84f0-4d57-9fff-a8e801080e98 --><!-- begin field 736a82fe-d241-4a91-8582-a8e801081132 --><h4>Pregnancy</h4><ul><li>Dipyridamole is not known to be harmful in pregnancy. However, the manufacturer advises that it should only be used if the benefits outweigh the possible risks.</li></ul><h4>Breastfeeding</h4><ul><li>Dipyridamole is excreted in breastmilk in small amounts.</li><li>The manufacturer advises that it should only be used during breastfeeding if essential.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>]</p><!-- end field 736a82fe-d241-4a91-8582-a8e801081132 --><!-- end item a6c25675-84f0-4d57-9fff-a8e801080e98 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}